{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T14:25:02Z","timestamp":1768314302518,"version":"3.49.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100006316","name":"Drug Research Academy, K\u00f8benhavns Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016217","name":"University of Malakand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016217","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001734","name":"K\u00f8benhavns Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007469","name":"Alfred Benzon Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007469","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000969","name":"Australian Academy of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000969","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.bcp.2011.09.002","type":"journal-article","created":{"date-parts":[[2011,9,10]],"date-time":"2011-09-10T02:25:53Z","timestamp":1315621553000},"page":"1971-1983","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["3-Hydroxy-2\u2032-methoxy-6-methylflavone: A potent anxiolytic with a unique selectivity profile at GABAA receptor subtypes"],"prefix":"10.1016","volume":"82","author":[{"given":"Nasiara","family":"Karim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Navnath","family":"Gavande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petrine","family":"Wellendorph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham A.R.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane R.","family":"Hanrahan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Chebib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2011.09.002_bib0005","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0031-6997(24)01363-2","article-title":"International Union of Pharmacology XV. Subtypes of gamma-aminobutyric acidA receptors: classification on the basis of subunit structure and receptor function","volume":"50","author":"Barnard","year":"1998","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.bcp.2011.09.002_bib0010","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrn1625","article-title":"Variations on an inhibitory theme: phasic and tonic activation of GABAA receptors","volume":"6","author":"Farrant","year":"2005","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.bcp.2011.09.002_bib0015","doi-asserted-by":"crossref","first-page":"41422","DOI":"10.1074\/jbc.M401354200","article-title":"Analysis of the set of GABAA receptor genes in the human genome","volume":"279","author":"Simon","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2011.09.002_bib0020","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1124\/pr.108.00505","article-title":"International Union of Pharmacology LXX. Subtypes of gamma-aminobutyric acid(A) receptors: classification on the basis of subunit composition, pharmacology, and function. Update","volume":"60","author":"Olsen","year":"2008","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.bcp.2011.09.002_bib0025","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0166-2236(96)80023-3","article-title":"Which GABAA-receptor subtypes really occur in the brain?","volume":"19","author":"McKernan","year":"1996","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.bcp.2011.09.002_bib0030","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.2174\/1381612054021024","article-title":"GABAA receptor channel pharmacology","volume":"11","author":"Johnston","year":"2005","journal-title":"Curr Pharm Design"},{"key":"10.1016\/j.bcp.2011.09.002_bib0035","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3109\/07853899708999348","article-title":"GABAA receptor subtypes: clinical efficacy and selectivity of benzodiazepine site ligands","volume":"29","author":"Korpi","year":"1997","journal-title":"Ann Med"},{"key":"10.1016\/j.bcp.2011.09.002_bib0040","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/0028-3908(83)90113-2","article-title":"Benzodiazepine receptor ligands with positive and negative efficacy","volume":"22","author":"Braestrup","year":"1983","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2011.09.002_bib0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0301-0082(93)90047-V","article-title":"The rapidly expanding range of neuronal benzodiazepine receptor ligands","volume":"40","author":"Gardner","year":"1993","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.bcp.2011.09.002_bib0050","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nm967","article-title":"Modifying quinolone antibiotics yields new anxiolytics","volume":"10","author":"Johnstone","year":"2004","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.bcp.2011.09.002_bib0055","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.2174\/156802611795371350","article-title":"GABAA receptor subtype-selective modulators I. \u03b12\/\u03b13-Selective agonists as non-sedating anxiolytics","volume":"11","author":"Atack","year":"2011","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.bcp.2011.09.002_bib0060","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/44579","article-title":"Benzodiazepine actions mediated by specific \u03b3-aminobutyric acid(A) receptor subtypes","volume":"401","author":"Rudolph","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2011.09.002_bib0065","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1126\/science.290.5489.131","article-title":"Molecular and neuronal substrate for the selective attenuation of anxiety","volume":"290","author":"Low","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.bcp.2011.09.002_bib0070","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/75761","article-title":"Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABAA receptor \u03b11 subtype","volume":"3","author":"McKernan","year":"2000","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.bcp.2011.09.002_bib0075","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1124\/jpet.300.1.2","article-title":"A new benzodiazepine pharmacology","volume":"300","author":"M\u00d6hler","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bcp.2011.09.002_bib0080","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1111\/j.1460-9568.2006.04775.x","article-title":"Both alpha2 and alpha3 GABAA receptor subtypes mediate the anxiolytic properties of benzodiazepine site ligands in the conditioned emotional response paradigm","volume":"23","author":"Morris","year":"2006","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.bcp.2011.09.002_bib0085","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0031-9422(00)00235-1","article-title":"Advances in flavonoid research since 1992","volume":"55","author":"Harborne","year":"2000","journal-title":"Phytochemistry"},{"key":"10.1016\/j.bcp.2011.09.002_bib0090","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/S0028-3908(99)00026-X","article-title":"Pharmacological studies on synthetic flavonoids: comparison with diazepam","volume":"38","author":"Griebel","year":"1999","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2011.09.002_bib0095","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0006-2952(02)01347-3","article-title":"Anxiolytic effect of wogonin, a benzodiazepine receptor ligand isolated from Scutellaria baicalensis Georgi","volume":"64","author":"Hui","year":"2002","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2011.09.002_bib0100","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2174\/156800705774322030","article-title":"Neuroactive flavonoids interacting with GABAA receptor complex","volume":"4","author":"Wang","year":"2005","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"key":"10.1016\/j.bcp.2011.09.002_bib0105","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1007\/s11064-009-9969-9","article-title":"The flavonoid glycosides, myricitrin, gossypin and naringin exert anxiolytic action in mice","volume":"34","author":"Fernandez","year":"2009","journal-title":"Neurochem Res"},{"key":"10.1016\/j.bcp.2011.09.002_bib0110","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.neuropharm.2008.06.069","article-title":"Flavan-3-ol derivatives are positive modulators of GABAA receptors with higher efficacy for the \u03b12 subtype and anxiolytic action in mice","volume":"55","author":"Fernandez","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2011.09.002_bib0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2004.03.014","article-title":"Flumazenil-independent positive modulation of gamma-aminobutyric acid action by 6-methylflavone at human recombinant \u03b11\u03b22\u03b32L and a \u03b11\u03b22 GABAA receptors","volume":"49","author":"Hall","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bcp.2011.09.002_bib0120","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1016\/0006-2952(88)90640-5","article-title":"High affinity of the naturally-occurring biflavonoid, amentoflavon, to brain benzodiazepine receptors in vitro","volume":"37","author":"Nielsen","year":"1988","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2011.09.002_bib0125","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ejphar.2005.06.036","article-title":"Determinants of amentoflavone interaction at the GABAA receptor","volume":"519","author":"Hansen","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bcp.2011.09.002_bib0130","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1111\/j.1476-5381.2010.01142.x","article-title":"Retrochalcone derivatives are positive allosteric modulators at synaptic and extrasynaptic GABAA receptors in vitro","volume":"162","author":"Jiang","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bcp.2011.09.002_bib0135","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1039\/jr9550000862","article-title":"A new synthesis of flavonols","author":"Gowan","year":"1955","journal-title":"J Chem Soc"},{"key":"10.1016\/j.bcp.2011.09.002_bib0140","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1039\/JR9560003224","article-title":"Aluminium complexes of flavonols","author":"Ballantine","year":"1956","journal-title":"J Chem Soc"},{"key":"10.1016\/j.bcp.2011.09.002_bib0145","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ejphar.2005.02.034","article-title":"6-Methylflavanone, a more efficacious positive allosteric modulator of \u03b3-aminobutyric acid (GABA) action at human recombinant \u03b12\u03b22\u03b32L than at \u03b11\u03b22\u03b32L and \u03b11\u03b22 GABAA receptors expressed in Xenopus oocytes","volume":"512","author":"Hall","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bcp.2011.09.002_bib0150","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1124\/jpet.105.090472","article-title":"Novel cyclic \u03b3-hydroxybutyrate (GHB) analogs with high affinity and stereoselectivity of binding to GHB sites in rat brain","volume":"315","author":"Wellendorph","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bcp.2011.09.002_bib0155","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/BF00401402","article-title":"comprehensive observational assessment: 1a. A systematic, quantitative procedure for assessing the behavioural and physiological state of the mouse","volume":"13","author":"Irwin","year":"1968","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.bcp.2011.09.002_bib0160","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1124\/jpet.108.146464","article-title":"Novel, potent, and selective GABAC antagonists inhibit myopia development and facilitate learning and memory","volume":"328","author":"Chebib","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bcp.2011.09.002_bib0165","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1476-5381.1985.tb08952.x","article-title":"The effects of triazolobenzodiazepines in two animal tests of anxiety and in the holeboard","volume":"86","author":"File","year":"1985","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bcp.2011.09.002_bib0170","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0014-2999(03)01274-3","article-title":"The mouse light\/dark box test","volume":"463","author":"Bourin","year":"2003","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bcp.2011.09.002_bib0175","first-page":"2029","article-title":"Neuro-pharmacological studies on SB 5833, a new psychotherapeutic agent of the benzodiazepine class","volume":"24","author":"Ferrini","year":"1974","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.bcp.2011.09.002_bib0180","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/BF00470579","article-title":"Benzodiazepine antagonist RO 15-1788: neurological and behavioral effects","volume":"78","author":"Bonetti","year":"1982","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2011.09.002_bib0185","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1111\/j.1476-5381.1991.tb12337.x","article-title":"GABAA receptors are differentially sensitive to zinc: dependence on subunit composition","volume":"103","author":"Smart","year":"1991","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bcp.2011.09.002_bib0190","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1124\/jpet.105.092403","article-title":"Pharmacological characterization of agonists at delta-containing GABAA receptors: functional selectivity for extrasynaptic receptors is dependent on the absence of gamma2","volume":"316","author":"Storustovu","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bcp.2011.09.002_bib0195","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.bcp.2009.12.024","article-title":"GABAA receptor subtype selectivity underlying anxiolytic effect of 6-hydroxyflavone","volume":"79","author":"Ren","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2011.09.002_bib0200","article-title":"2\u2032-Methoxy-6-methylflavone: a novel anxiolytic and sedative with subtype selective activating and modulating actions at GABA-A receptors","author":"Karim","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bcp.2011.09.002_bib0205","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1124\/jpet.104.070342","article-title":"Compounds exhibiting selective efficacy for different \u03b2 subunits of human recombinant \u03b3-aminobutyric acidA receptors","volume":"311","author":"Smith","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bcp.2011.09.002_bib0210","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1523\/JNEUROSCI.22-05-01541.2002","article-title":"Enhanced neurosteroid potentiation of ternary GABAA receptors containing the delta subunit","volume":"22","author":"Wohlfarth","year":"2002","journal-title":"J Neurosci"},{"key":"10.1016\/j.bcp.2011.09.002_bib0215","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1124\/mol.104.003426","article-title":"Multiple actions of propofol on \u03b1\u03b2\u03b3 and \u03b1\u03b2\u03b4 GABAA receptors","volume":"66","author":"Feng","year":"2004","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bcp.2011.09.002_bib0220","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.freeradbiomed.2004.08.002","article-title":"Flavonoids and the brain: interactions at the blood\u2013brain barrier and their physiological effects on the central nervous system","volume":"37","author":"Youdim","year":"2004","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.bcp.2011.09.002_bib0225","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/sj.bjp.0705828","article-title":"The flavone hispidulin, a benzodiazepine receptor ligand with positive allosteric properties, traverses the blood\u2013brain barrier and exhibits anticonvulsive effects","volume":"142","author":"Kavvadias","year":"2004","journal-title":"Br J Pharmacol"},{"issue":"Suppl. 1","key":"10.1016\/j.bcp.2011.09.002_bib0230","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/S0367-326X(00)00186-6","article-title":"Behavioral characterisation of the flavonoids apigenin and chrysin","volume":"71","author":"Zanoli","year":"2000","journal-title":"Fitoterapia"},{"key":"10.1016\/j.bcp.2011.09.002_bib0235","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/nprot.2007.44","article-title":"The use of the elevated plus maze as an assay of anxiety-related behavior in rodents","volume":"2","author":"Walf","year":"2007","journal-title":"Nat Protocols"},{"key":"10.1016\/j.bcp.2011.09.002_bib0240","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0149-7634(85)90030-2","article-title":"Exploratory behavior models of anxiety in mice","volume":"9","author":"Crawley","year":"1985","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.bcp.2011.09.002_bib0245","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1124\/jpet.102.042960","article-title":"Deletion of the \u03b11 or \u03b22 subunit of GABAA receptors reduces actions of alcohol and other drugs","volume":"304","author":"Blednov","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bcp.2011.09.002_bib0250","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1126\/science.2422758","article-title":"Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor","volume":"232","author":"Majewska","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.bcp.2011.09.002_bib0255","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/nrn1703","article-title":"Neurosteroids: endogenous regulators of the GABAA receptor","volume":"6","author":"Belelli","year":"2005","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.bcp.2011.09.002_bib0260","doi-asserted-by":"crossref","first-page":"12905","DOI":"10.1073\/pnas.96.22.12905","article-title":"Attenuated sensitivity to neuroactive steroids in \u03b3-aminobutyrate type A receptor delta subunit knockout mice","volume":"96","author":"Mihalek","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bcp.2011.09.002_bib0265","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/BF00432116","article-title":"Effects of THIP on chronic anxiety","volume":"80","author":"Hoehn-Saric","year":"1983","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.bcp.2011.09.002_bib0270","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.pharmthera.2006.05.004","article-title":"Low dose acute alcohol effects on GABAA receptor subtypes","volume":"112","author":"Wallner","year":"2006","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bcp.2011.09.002_bib0275","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.neuropharm.2009.12.023","article-title":"Pharmacological characterization of a novel positive modulator at alpha4 beta3 delta-containing extrasynaptic GABAA receptors","volume":"58","author":"Hoestgaard-Jensen","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2011.09.002_bib0280","doi-asserted-by":"crossref","first-page":"8980","DOI":"10.1073\/pnas.142288699","article-title":"Trace fear conditioning involves hippocampal \u03b15 GABAA receptors","volume":"99","author":"Crestani","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bcp.2011.09.002_bib0285","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S0026-895X(24)12233-X","article-title":"Molecular targets for the myorelaxant action of diazepam","volume":"59","author":"Crestani","year":"2001","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bcp.2011.09.002_bib0290","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1124\/jpet.105.089920","article-title":"TPA023 [7-(1,1- dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b] pyridazine], an agonist selective for alpha2- and alpha3-containing GABAA receptors, is a nonsedating anxiolytic in rodents and primates","volume":"316","author":"Atack","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bcp.2011.09.002_bib0295","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1124\/jpet.109.161885","article-title":"Limiting activity at beta1-subunit-containing GABAA receptor subtypes reduces ataxia","volume":"332","author":"Gee","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bcp.2011.09.002_bib0300","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/nn1398","article-title":"Alcohol-induced motor impairment caused by increased extrasynaptic GABAA receptor activity","volume":"8","author":"Hanchar","year":"2005","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.bcp.2011.09.002_bib0305","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1517\/13543784.14.5.601","article-title":"The benzodiazepine binding site of GABAA receptors as a target for the development of novel anxiolytics","volume":"14","author":"Atack","year":"2005","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.bcp.2011.09.002_bib0310","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.coph.2005.08.005","article-title":"GABAA receptors: a viable target for novel anxiolytics?","volume":"6","author":"Whiting","year":"2006","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.bcp.2011.09.002_bib0315","doi-asserted-by":"crossref","first-page":"7380","DOI":"10.1073\/pnas.0502579102","article-title":"Selective anxiolysis produced by ocinaplon, a GABAA receptor modulator","volume":"102","author":"Lippa","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bcp.2011.09.002_bib0320","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.neuropharm.2006.09.013","article-title":"The novel anxiolytic ELB139 displays selectivity to recombinant GABAA receptors different from diazepam","volume":"52","author":"Rabe","year":"2007","journal-title":"Neuropharmacology"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295211006824?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295211006824?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:01:29Z","timestamp":1762095689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295211006824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":64,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0006295211006824"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2011.09.002","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"3-Hydroxy-2\u2032-methoxy-6-methylflavone: A potent anxiolytic with a unique selectivity profile at GABAA receptor subtypes","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2011.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}